Skip to contentV
Viridian Therapeutics, Inc.
V
VRDNViridian Therapeutics, Inc. Q1 2025 · 10-Q
Revenue$72.00K$72.00K±0.0% vs Q1 2024 Net Income-$86.91M-$86.91MN/M vs Q1 2024 EPS, diluted—
Operating Income-$93,866,000N/M Operating Cash Flow-$92,653,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Viridian Therapeutics, Inc. · CIK 1590750 · Engraved from SEC EDGAR
Free Cash Flowderived-$92,739,000N/M Margins · derivedOperating margin-130369.4%−52734.7 pt vs Q1 2024
Net margin-120711.1%−53291.7 pt vs Q1 2024
ended Mar 31, 2025 · filed May 6, 2025 · 36 d after period end